BJDX_OUT_1 [2025-04-04 16:26:04 -0400] 2948 Bytes | 770 tokens | Cum: 770 tkns (9.62% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Bluejay Diagnostics (BJDX) hit my radar screen, up to 4.49 from a prev close of 3.25 Do you think its got more juice or is it lacking potential? It's 4:26:02 PM on Fri Apr 04, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Bluejay Diagnostics (BJDX)
IPO: 2021-11-10 (3 Years Ago)
Market Cap: $1,713,903
Shares Outstanding: 550,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Here’s the first list of news for Bluejay Diagnostics:

C1 - Nov-13-24 05:10PM - Bluejay Diagnostics Announces Reverse Stock Split
C2 - Jun-28-24 11:32AM - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
C3 - Jun-27-24 08:58AM - Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
C4 - Jun-27-24 08:58AM 07:34AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
C5 - Jun-26-24 08:00AM - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
C6 - Jun-17-24 08:00AM - Bluejay Diagnostics Announces Reverse Stock Split
C7 - Jun-17-24 08:00AM 07:40AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
C8 - Mar-28-24 11:53PM - BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Bluejay Diagnostics (BJDX).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

BJDX_OUT_3 [2025-04-04 16:26:09 -0400] 1098 Bytes | 285 tokens | Cum: 1057 tkns (13.21% of 8k)
==========================================================================

Showing C8 (chunk 1 of 2): C8:
**BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023**
Date: Mar-28-24 11:53PM
Source: (InvestorPlace)
URL: https://investorplace.com/earning-results/2024/03/bjdx-stock-earnings-bluejay-diagnostics-for-q4-of-2023/

Bluejay Diagnostics just reported results for the fourth quarter of 2023

Bluejay Diagnostics(NASDAQ:BJDX) just reported results for the fourth quarter of 2023.

InvestorPlace Earnings is a project that leverages data fromTradeSmithto automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].

Article printe

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BJDX_OUT_5 [2025-04-04 16:26:10 -0400] 511 Bytes | 130 tokens | Cum: 1284 tkns (16.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T21:06:20Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Apogee Therapeutics (NASDAQ:APGE),...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BJDX_OUT_7 [2025-04-04 16:26:17 -0400] 1098 Bytes | 334 tokens | Cum: 1620 tkns (20.25% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Thursday's After-Market Session - Apogee Therapeutics (NASDAQ:APGE), Bluejay Diagnostics (NASDAQ:BJDX)**Date: 2025-03-20Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44426746/12-health-care-stocks-moving-in-thursdays-after-market-sessionGainers Impact BioMedical IBO stock moved upwards by 98.1% to $4.12 during Thursday's after-market session. The company's market cap stands at $47.3 million. Apogee Therapeutics APGE shares increased by 10.7% to $44.69. The market value of their outstanding shares is at $2.5 billion. Intensity Therapeutics INTS shares moved upwards by 9.32% to $2.11. The company's market cap stands at $32.0 million. Wellgistics Health WGRX shares moved upwards by 8.52% to $5.14. The company's market cap stands at $266.9 million. Bluejay Diagnostics BJDX shar

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BJDX_OUT_9 [2025-04-04 16:26:18 -0400] 946 Bytes | 291 tokens | Cum: 2070 tkns (25.87% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-28T15:32:00Z - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
B2 - 2024-06-26T12:00:00Z - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
B3 - 2024-01-29T12:56:17Z - Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
B4 - 2024-01-02T22:58:00Z - Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
B5 - 2023-12-28T19:32:49Z - Gold Moves Lower; US Crude Stocks Decline Last Week
B6 - 2023-12-28T18:07:18Z - Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BJDX_OUT_11 [2025-04-04 16:26:21 -0400] 1107 Bytes | 286 tokens | Cum: 2358 tkns (29.48% of 8k)
==========================================================================

Showing B1 (chunk 1 of 2): B1:
**Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/28/2906037/0/en/Bluejay-Diagnostics-Announces-Closing-of-8-75-Million-Underwritten-Public-Offering.htmlACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BJDX_OUT_13 [2025-04-04 16:26:22 -0400] 1002 Bytes | 308 tokens | Cum: 2740 tkns (34.25% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis together with our Cons Fin Stmnts and the notes thereto included elsewhere in this Form 10-K. This discussion co...

S2 - 2024-11-07 10-Q PART I - FIN INFO

Item 1. Condensed Cons Fin Stmnts.

Bluejay Diagnostics, Inc.

Condensed Cons Balance Sheets (Unaudited)

September 30,

December 31,

2024 2023 ASSETS Curr assets: Cash and cash equiv $ 5,755,741 $ 2,20...

S3 - 2024-08-14 10-Q PART I - FIN INFO

Item 1. Condensed Cons Fin Stmnts.

Bluejay Diagnostics, Inc.

Condensed Cons Balance Sheets (Unaudited)

June 30, 2024 December 31, 2023 ASSETS Curr assets: Cash and cash equiv $ 8,058,415 $ 2,208,516 Prepa...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BJDX_OUT_15 [2025-04-04 16:26:23 -0400] 1098 Bytes | 238 tokens | Cum: 2980 tkns (37.25% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis together with our Consolidated Financial Statements and the notes thereto included elsewhere in this Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. For additional discussion, see CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS above.

Overview

We are a clinical-stage medical diagnostics company developing rapid tests using whole blood on our Symphony platform (Symphony) to improve patient outcomes in critical care settings. Our Symphony technology platform is an exclusively licensed, patented system that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (FDA), could provide a solution to

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BJDX_OUT_17 [2025-04-04 16:26:27 -0400] 1098 Bytes | 267 tokens | Cum: 3249 tkns (40.61% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): a significant market need in the United States. Clinical trials indicate Symphony produces laboratory-quality results in less than 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs), where rapid and reliable results are required.

Since inception, we have incurred net losses from operations each year and we expect to continue to incur losses for the foreseeable future. We incurred net losses of approximately $7.7 million and $10.0 million for the years ended December 31, 2024 and 2023, respectively. We had negative cash flow from operating activities of approximately $7.5 million and $8.3 million for the years ended December 31, 2024 and 2023, respectively, and had an accumulated deficit of approximately $34.7 million and $26.95 million as of December 31, 2024 and 2023, respectively.

Results of Operations

Comparison of Years Ended

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BJDX_OUT_19 [2025-04-04 16:26:37 -0400] 4810 Bytes | 1306 tokens | Cum: 4681 tkns (58.51% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------------+
| Volume: 671,774 | Perf Month: -17.14% | Option/Short: No / Yes | Sales Y/Y TTM: -100.00% |
+--------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 51.13K | Perf Quarter: -22.93% | Short Float: 1.09% | ROE: -178.98% |
+--------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 13.14 | Index: - | Short Ratio: 0.12 | ROI: -358.14% |
+--------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 43.84 | Market Cap: 1.96M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.46 | Shs Outstand: 0.55M | Beta: 0.33 | EPS Surprise: -155.21% |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA20: -9.36% | Shs Float: 0.55M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA50: -7.89% | Inst Own: 0.45% | Sales past 5Y: -20.00% | Earnings: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA200: -73.03% | Insider Own: 0.29% | Employees: 7 | |
+--------------------+-----------------------+------------------------+-------------------------+
| Perf Week: -7.35% | Insider Trans: 0.00% | Debt/Eq: 0.04 | |
+--------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading if any are accessible.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1481959.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.53
Average Volume: 76063.83
30-Day High: 4.399
30-Day Low: 3.25

[Detailed Financials: Q3 2024]
- Total Assets: $8,353,410.0
- Total Liabilities: $1,188,976.0
- Total Equity: $7,164,434.0
- Current Assets: $6,567,686.0
- Current Liabilities: $1,049,247.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.16

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-2,302,674.0

[Detailed Financials: Q2 2024]
- Total Assets: $10,859,211.0
- Total Liabilities: $2,218,136.0
- Total Equity: $8,641,075.0
- Current Assets: $9,018,408.0
- Current Liabilities: $2,056,882.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.12

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $5,397,246.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

BJDX_OUT_21 [2025-04-04 16:26:38 -0400] 687 Bytes | 169 tokens | Cum: 5119 tkns (63.99% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

BJDX_IN_23 [2025-04-04 16:26:39 -0400] 126 Bytes | 29 tokens | Cum: 5178 tkns (64.72% of 8k)
==========================================================================

====================================
[2025-04-04 16:26:39] # Analysis Completed
Elapsed Time: 36.53 seconds